Evenamide meets primary endpoint in phase 2/3 study of patients with schizophrenia

Newron Pharmaceuticals announced positive topline results from a phase 2/3 study of evenamide for patients with chronic schizophrenia who have an inadequate response to current antipsychotic therapy. The study met its primary endpoint of improvement on the Positive and Negative Syndrome Scale (PANSS). Evenamide was well-tolerated, with no new safety concerns identified. A key secondary endpoint — improvement in the Clinical Global Impressions scale — was also met. The addition of evenamide to patients’ current antipsychotic therapy was associated with a highly statistically significant reduction in PANSS total score. Headache, vomiting, and nasopharyngitis were the most common adverse events associated with evenamide.

Source link

error: Content is protected !!